The Effect of Oxygen Application With Double Nasal Cannula on Respiratory Complications

NCT ID: NCT06273319

Last Updated: 2024-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-15

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare desaturation and respiratory complications by applying oxygen therapy with double nasal cannula to patients who are planned to undergo gastrointestinal endoscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Two groups of patients scheduled for gastrointestinal endoscopy will be compared in terms of desaturation and respiratory complications by applying 15 litres of oxygen therapy to the first group and 30 litres to the second group with double nasal cannula.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Disease Gastric Distress

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
2

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Patients who will receive 15 litres oxygen therapy

: Patients who will receive 15 litres oxygen therapy, will be applied throughout the transaction.Patient saturation and complications such as bronchospasm and laryngospasm respiratory arrest will be recorded throughout the procedure.

Group Type PLACEBO_COMPARATOR

OXYGEN THERAPY

Intervention Type DRUG

15 AND 30 LT OXYGEN TREATMENT

Group 2: Patients who will receive 30 litres oxygen therapy

Patients who will receive 30 litres oxygen therapy,will be applied throughout the transaction.Patient saturation and complications such as bronchospasm and laryngospasm respiratory arrest will be recorded throughout the procedure.

Group Type ACTIVE_COMPARATOR

OXYGEN THERAPY

Intervention Type DRUG

15 AND 30 LT OXYGEN TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OXYGEN THERAPY

15 AND 30 LT OXYGEN TREATMENT

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

18-65 years old

PATIENTS WHO WILL HAVE ENDOSCOPY AND OR COLONOSCOPY

Exclusion Criteria

* Chronic obstructive pulmonary disease Having low saturation Lung cancer
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Inonu University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

DUYGU DEMİROZ

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Inonu universitesi

Malatya, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

DUYGU DEMIROZ, dr

Role: CONTACT

+905319504421

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

010656

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.